16
Participants
Start Date
July 7, 2023
Primary Completion Date
November 20, 2024
Study Completion Date
November 20, 2024
IMSA101
Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
Immune checkpoint inhibitor
1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
PULSAR
1st day of Cycles 1, 2 and 3.
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Montefiore Medical Center, The Bronx
Louis Stokes Cleveland VA Medical Center, Cleveland
MetroHealth Medical Center, Cleveland
University of Wisconsin Hospital and Clinics, Madison
Northwestern Memorial Hospital, Chicago
University of Chicago Medical Center, Chicago
Washington University School of Medicine, St Louis
UT Southwestern Medical Center, Dallas
Baylor College of Medicine Medical Center, Houston
USC/Norris Comprehensive Cancer Center, Los Angeles
UCLA, Los Angeles
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston
Lead Sponsor
ImmuneSensor Therapeutics Inc.
INDUSTRY